BRCA2 and breast cancer: In the current study, we found that 40 patients had deleterious mutations in BRCA1 and BRCA2 genes, with a total prevalence of 39.6%, which is higher than that reported in a number of previous studies on familial BC patients in Middle East countries, such as Lebanon [34], Bahrain [35], and Saudi Arabia [36].